Benzinga | Apr 6, 2021 07:36AM EDT

Progenity And Ionis Pharmaceuticals Enter Agreement To Evaluate Progenity's Ingestible Oral Biotherapeutics Technology For Delivery Of Antisense Therapies

Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity's Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides, developed and manufactured by Ionis.